Proactive Investors - Run By Investors For Investors

OBJ's array-back hydrogel technology study delivers promising results

The company's slow release technology may have applications that are beneficial for the ageing population.
Picture of knee guard
92% of participants considered themselves either better or much better following the active patch treatment

OBJ Limited (ASX:OBJ) has received a promising report from Curtin University’s School of Physiotherapy and Exercise Science for a study into slow release technology for the delivery of medications.

The report outlines the results of a double-blind study into the clinical outcomes following a 48-hour administration of a magnetophoresis enhanced transdermal Ibuprofen (5%) patch.

The study sought to demonstrate that OBJ’s array-back hydrogel technology could be used with third-party therapeutic drugs such as ibuprofen.

Applications for ageing population

Ibuprofen and many other similar anti-inflammatory drugs cannot be taken in tablet form for extended periods due to their impact on other organs.

OBJ’s slow-release technology could potentially be an ideal resolution to the problem, and the fact that its target markets could include the ageing population is a positive.

Broad-based results demonstrate pain reduction

There were significant differences between the active patch session and the placebo patch session for all primary outcome measures.

This indicated that participants experienced less pain and improved function during the 48-hour active patch session.

There were also significant improvements across most of the secondary outcome measures with few skin reactions to either placebo or active patches.

Slight skin redness was reported by five participants with the active patches and six participants with the placebo patches, and all associated this with the adhesive tape rather than the gel.

Impressive active knee guard device results

The results were particularly encouraging in relation to OBJ’s active knee guard device containing ibuprofen (5%).

Combined with magnetophoresis, this produced a significantly greater reduction in pain and improvement in function than the placebo device.

There was a significant improvement in participants suffering from movement-related pain.

Twenty-two participants (92%) considered themselves either better or much better following the active patch treatment.

View full OBJ profile View Profile

OBJ Ltd Timeline

Newswire
January 25 2016
Newswire
December 02 2014

Related Articles

blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
blood
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use